Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Maurel, Joan"" wg kryterium: Autor


Wyświetlanie 1-6 z 6
Tytuł:
Metabolic interventions to enhance immunotherapy and targeted therapy efficacy in advanced colorectal cancer.
Autorzy:
Oliveres H; Medical Oncology Department, Hospital Clinic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Barcelona, Spain.
Cascante M; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Department of Biochemistry and Molecular Biomedicine and Institute of Biomedicine (IBUB), Universitat de Barcelona, Barcelona, Spain. Electronic address: .
Maurel J; Medical Oncology Department, Hospital Clinic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Electronic address: .
Pokaż więcej
Źródło:
Current opinion in chemical biology [Curr Opin Chem Biol] 2023 Dec; Vol. 77, pp. 102401. Date of Electronic Publication: 2023 Oct 06.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Colorectal Neoplasms*/drug therapy
Humans ; Immunotherapy ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients.
Autorzy:
Alonso V; Medical Oncology Service, Hospital Universitario Miguel Servet, Zaragoza, Spain. Electronic address: .
Escudero P; Medical Oncology Service, Hospital Universitario Lozano Blesa, Zaragoza, Spain. Electronic address: .
Fernández-Martos C; Medical Oncology Department, Fundación Instituto Valenciano de Oncologia, Valencia, Spain. Electronic address: .
Salud A; Medical Oncology Service, Hospital Universitari Arnau de Vilanova, Lleida, Spain. Electronic address: .
Méndez M; Medical Oncology Service, Hospital de Móstoles, Móstoles, Spain. Electronic address: .
Gallego J; Medical Oncology Service, Hospital General Universitario of Elche, Elche, Spain. Electronic address: .
Rodriguez JR; Medical Oncology Service, Hospital Infanta Cristina, Badajoz, Spain. Electronic address: .
Martín-Richard M; Medical Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Electronic address: .
Fernández-Plana J; Medical Oncology Service, Hospital Mutua de Terrasa, Spain. Electronic address: .
Manzano H; Medical Oncology Service, Hospital Son Espases, Palma, Spain. Electronic address: .
Méndez JC; Medical Oncology Service, Centro Oncologico de Galicia, A Coruña, Spain. Electronic address: .
Zanui M; Medical Oncology Service, Hospital de Mataró, Mataró, Spain. Electronic address: .
Falcó E; Medical Oncology Service, Hospital Son Llàtzer, Palma, Spain. Electronic address: .
Gil-Raga M; Medical Oncology Service, Hospital de Sagunto, Sagunto, Spain. Electronic address: .
Rojo F; Pathology Service, Hospital Fundación Jiménez Díaz, Madrid, Spain. Electronic address: .
Cuatrecasas M; Department of Pathology, Hospital Clínic de Barcelona, Barcelona, Spain. Electronic address: .
Feliu J; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain. Electronic address: .
García-Albéniz X; Department of Oncology, Harvard School of Public Health, Boston (MA), United States of America. Electronic address: .
Maurel J; Medical Oncology Department, Hospital Clinic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, University of Barcelona, Barcelona, Spain. Electronic address: .
Pokaż więcej
Źródło:
Neoplasia (New York, N.Y.) [Neoplasia] 2018 Jul; Vol. 20 (7), pp. 678-686. Date of Electronic Publication: 2018 May 26.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Gene Expression*
Antibodies, Monoclonal/*pharmacology
Cetuximab/*pharmacology
Colorectal Neoplasms/*genetics
Colorectal Neoplasms/*pathology
Matrix Metalloproteinase 7/*genetics
Receptor, IGF Type 1/*genetics
ras Proteins/*genetics
Aged ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/metabolism ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Matrix Metalloproteinase 7/metabolism ; Middle Aged ; Mutation ; Panitumumab ; Prognosis ; Proportional Hazards Models ; Proto-Oncogene Proteins B-raf/genetics ; Receptor, IGF Type 1/metabolism
Czasopismo naukowe
Tytuł:
Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients.
Autorzy:
Negrouk A; International Policy Office, European Organisation for Research and Treatment of Cancer (EORTC),Headquarters, Brussels, Belgium.
Lacombe D; Director General, European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium.
Cardoso F; Champalimaud Cancer Center, Lisboa, Portugal.
Morin F; French Cooperative Thoracic Intergroup (IFCT) - Groupes Cooperateurs en Oncologie (GCO), Paris, France.
Carrasco E; Grupo Español de Investigación en Cáncer de Mama (GEICAM), Scientific Director and CEO, Madrid, Spain.
Maurel J; Grupo Espanol Multidisciplinar en Cancer Digestivo (GEMCAD), Medical OncologyDepartment, Hospital Clínic, Translational Genomics and Targeted Therapeuticsin Solid Tumors Group, IDIBAPS, University of Barcelona, Barcelona, Spain.
Maibach R; International Breast Cancer Study Group (IBCSG) Coordinating Center, Bern, Switzerland.
Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), InstitutoSanitario de Investigación Biomédica de Córdoba (IMIBIC), Medical OncologyDepartment, Hospital Universitario Reina Sofía, Córdoba, Spain.
Marais R; European Association for Cancer Research (EACR), Department of Molecular Oncology at the University of Manchester and Directorof the Cancer Research UK Manchester Institute, Manchester, UK.
Stahel RA; European Society for Medical Oncology (ESMO), Clinic of Oncology,University Hospital, Zürich, Zurich, Switzerland.
Pokaż więcej
Źródło:
ESMO open [ESMO Open] 2017 Aug 03; Vol. 2 (3), pp. e000187. Date of Electronic Publication: 2017 Aug 03 (Print Publication: 2017).
Typ publikacji:
Journal Article
Czasopismo naukowe
Tytuł:
Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer.
Autorzy:
Eckhardt SG; Developmental Therapeutics and GI Malignancies, University of Colorado Health Sciences Center, Aurora, Colorado 80045, USA. />De Porre P
Smith D
Maurel J
Steward WP
Bouche O
van de Velde H
Michiels B
Bugat R
Pokaż więcej
Źródło:
Journal of pain and symptom management [J Pain Symptom Manage] 2009 Feb; Vol. 37 (2), pp. 135-43. Date of Electronic Publication: 2008 Aug 23.
Typ publikacji:
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Adenocarcinoma/*drug therapy
Adenocarcinoma/*mortality
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Pain/*mortality
Pain/*prevention & control
Pancreatic Neoplasms/*drug therapy
Pancreatic Neoplasms/*mortality
Patient Satisfaction/*statistics & numerical data
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents ; Comorbidity ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Double-Blind Method ; Europe/epidemiology ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Outcome Assessment, Health Care ; Pain Measurement/drug effects ; Placebo Effect ; Quinolones/administration & dosage ; Risk Assessment ; Risk Factors ; Survival Analysis ; Survival Rate ; Treatment Outcome ; United States/epidemiology ; Gemcitabine
Czasopismo naukowe
Tytuł:
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study.
Autorzy:
Spano JP; Hôpital de la Pitié Salpêtrière, Paris, France. />Chodkiewicz C
Maurel J
Wong R
Wasan H
Barone C
Létourneau R
Bajetta E
Pithavala Y
Bycott P
Trask P
Liau K
Ricart AD
Kim S
Rixe O
Pokaż więcej
Źródło:
Lancet (London, England) [Lancet] 2008 Jun 21; Vol. 371 (9630), pp. 2101-8. Date of Electronic Publication: 2008 May 29.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Antimetabolites, Antineoplastic/*therapeutic use
Deoxycytidine/*analogs & derivatives
Imidazoles/*therapeutic use
Indazoles/*therapeutic use
Pancreatic Neoplasms/*drug therapy
Receptors, Vascular Endothelial Growth Factor/*antagonists & inhibitors
Adult ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/adverse effects ; Axitinib ; Deoxycytidine/adverse effects ; Deoxycytidine/therapeutic use ; Drug Therapy, Combination ; Female ; Humans ; Imidazoles/administration & dosage ; Imidazoles/adverse effects ; Indazoles/administration & dosage ; Indazoles/adverse effects ; Male ; Middle Aged ; Pancreatic Neoplasms/mortality ; Pancreatic Neoplasms/pathology ; Proportional Hazards Models ; Survival Rate ; Gemcitabine
Czasopismo naukowe
    Wyświetlanie 1-6 z 6

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies